Back to Newsroom

Novira Therapeutics to Present at 2015 AASLD Meeting in San Francisco

DOYLESTOWN, Pa., Oct. 20, 2015 /PRNewswire/ — Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that it will present two posters and one oral presentation for its core inhibitors, including its lead candidate, NVR 3-778, at the upcoming 2015 annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Click here to read more